Welcome to our dedicated page for Purple Biotech news (Ticker: PPBT), a resource for investors and traders seeking the latest updates and insights on Purple Biotech stock.
Purple Biotech Ltd (PPBT) is a clinical-stage oncology innovator developing therapies to combat tumor resistance mechanisms. This hub provides investors and researchers with timely updates on the company’s pipeline progress, including its dual inhibitor NT219, CEACAM1-targeting CM24 antibody, and tri-specific antibody platform.
Key resources include: Press releases detailing clinical trial milestones for lead candidates, partnership announcements with pharmaceutical collaborators, and regulatory filings related to drug development. Users will find analysis of preclinical data alongside updates on combination therapy strategies involving immunotherapies.
Bookmark this page to efficiently track PPBT’s advancements in overcoming immune evasion through novel mechanisms like STAT3 inhibition and localized immune activation. Check regularly for new insights into trial designs, biomarker analyses, and strategic initiatives shaping the future of precision oncology.
Purple Biotech announced final data from its Phase 2 study of CM24 in pancreatic cancer patients at AACR 2025. The study showed significant efficacy in biomarker-enriched subgroups, with up to 90% reduction in death risk in specific patient populations.
Key findings include:
- 78% reduction in death risk for patients with specific CEACAM1 ranges
- 61% reduction in death risk for patients with defined CEACAM1 or MPO levels
- 90% reduction in death risk for patients with high tumor CEACAM1 and low PD-L1 CPS
The combination therapy of CM24, nivolumab, and chemotherapy was well-tolerated and showed improvements in all efficacy measures. The study identified CEACAM1 as a potential biomarker, both in serum and tumor tissue. Based on these results, Purple Biotech plans to conduct a biomarker-driven Phase 2b study, potentially expanding into gastric and biliary tract cancer treatments.
Purple Biotech (NASDAQ/TASE: PPBT) presented new data for NT219, their dual inhibitor of IRS1/2 and STAT3, at AACR 2025. The company revealed positive findings from two posters focusing on colorectal and head and neck cancers.
Key findings include:
- NT219 shows potential in overcoming immune evasion mechanisms and restoring immunotherapy efficacy in head and neck squamous cell carcinoma (HNSCC)
- Upregulation of pIGF1R and pSTAT3 correlated with patient response, suggesting potential biomarkers
- In colorectal cancer, APC-loss or enhanced wnt/β-catenin signaling may serve as biomarkers for NT219 treatment effectiveness
- The drug demonstrated ability to reverse chemo-resistance and synergize with approved chemotherapy in multiple models
Purple Biotech (NASDAQ/TASE: PPBT) announced the publication of a study in Neuro Oncology journal demonstrating NT219's potential to suppress brain metastasis in colorectal cancer. The research, conducted at Tel Aviv University and Sourasky Medical Center, reveals that NT219 combined with 5-flourouracil (5-FU) effectively inhibits colorectal cancer brain metastasis through the IRS2 pathway.
The study analyzed over 35,000 colorectal cancer samples, identifying IRS2 as a key driver of brain metastasis. NT219, a first-in-class small molecule drug, works by degrading IRS1/2 and blocking downstream signaling. The research shows particular promise for colorectal cancer patients, of whom 20% have distant metastasis at diagnosis and 50% develop metastasis later.
Purple Biotech is advancing NT219 into a Phase 2 study for recurrent/metastatic squamous cell carcinoma of the head and neck, with potential expansion into colorectal and other cancers.
Purple Biotech (NASDAQ/TASE: PPBT), a clinical-stage company focused on developing first-in-class therapies for tumor immune evasion and drug resistance, has announced its participation in the Canaccord Genuity Horizons in Oncology Virtual Conference.
CEO Gil Efron will join a panel discussion titled 'New Radiotherapy and Targeted Therapy Approaches' scheduled for April 7, 2025, from 2:00 PM to 2:50 PM ET. The company's management team will also be available for one-on-one meetings during the conference.
Purple Biotech (NASDAQ/TASE: PPBT) announced three poster presentations at the upcoming 2025 American Association for Cancer Research Meeting in Chicago from April 25-30. The presentations will showcase:
- Final analysis of Phase 2 cohort study of CM24 combined with nivolumab and chemotherapy in pancreatic cancer, including potential serum biomarkers
- Research on APC-loss as a potential biomarker for NT219 treatment in colorectal cancer
- Study of NT219's ability to overcome immune evasion-resistant mechanisms in head and neck squamous cell carcinoma
Purple Biotech (NASDAQ/TASE: PPBT) announced its Q4 and full-year 2024 financial results, highlighting successful clinical trials for its oncology assets. The company reported positive final results from CM24's Phase 2 study in pancreatic cancer, showing a 79% reduction in death risk for biomarker-selected patients. NT219 is advancing to Phase 2 trials for head and neck cancer in combination with pembrolizumab and cetuximab.
Financial highlights for Q4 2024 include:
- Research and Development expenses decreased 90.4% to $0.5 million
- Operating loss reduced 84.1% to $1 million
- Net loss decreased to $0.4 million ($0.2 per basic ADS)
- Cash position of $8.2 million, providing runway into mid-2026
The company raised $2.8 million through a registered direct offering and an additional $1.5 million through ADS sales. The CAPTN-3 platform showed promising preclinical data, demonstrating sustained tumor regression in triple-negative breast cancer models.
Purple Biotech (NASDAQ/TASE: PPBT) has received a new U.S. patent for NT219 in combination with EGFR antibody therapy for cancer treatment. The patent covers NT219's use with cetuximab (Erbitux) and other EGFR antibodies like panitumumab and necitumumab in treating EGFR therapy-resistant tumors.
NT219, a first-in-class small molecule drug targeting cancer resistance mechanisms, has advanced to Phase 2 clinical trials for second-line patients with recurrent and/or metastatic head and neck cancer. The study will evaluate the drug's effectiveness when combined with standard therapies including cetuximab and pembrolizumab.
The head and neck cancer treatment market is projected to reach $5 billion by 2030. This patent complements Purple Biotech's existing IP portfolio, which includes protection in major markets like Europe, China, and Japan.
Purple Biotech (NASDAQ/TASE: PPBT) is advancing NT219 into Phase 2 trials for head and neck cancer treatment. The study will evaluate NT219, a first-in-class small molecule drug, in combination with standard treatments pembrolizumab (Keytruda) or cetuximab (Erbitux) for recurrent/metastatic squamous cell carcinoma (R/M SCCHN).
The trial, conducted with the University of Colorado Anschutz Medical Campus, will follow a Simon 2-stage approach with two single-arm cohorts, initially enrolling 10 patients per arm, followed by 19 additional patients per arm in the second stage. The SCCHN market is projected to reach $5 billion by 2030, with current treatment response rates at only 20% for pembrolizumab and 15-20% for cetuximab.
NT219 targets cancer resistance mechanisms by degrading IRS1/2 and blocking IGF1R/IRS1 and STAT3 survival pathways. Phase 1 studies have already determined the recommended dose and demonstrated anti-tumor activity with confirmed patient responses.
Purple Biotech (NASDAQ/TASE: PPBT) has announced a research collaboration with the Icahn School of Medicine at Mount Sinai to study their CAPTN-3 tri-specific antibody platform. The collaboration will explore how CAPTN-3 regulates NK and T cells within the tumor microenvironment (TME), aiming to enhance tumor-specific immunity against various cancer types.
The CAPTN-3 antibodies are designed to promote antitumor functions through three mechanisms: conditional activation of the anti-CD3 arm at the TME, blockade of NKG2A, and targeting tumor-specific antigens. This approach could potentially improve responses in resistant cancer patients and overcome current therapy limitations.
The research will be led by Dr. Amir Horowitz, Associate Professor at Mount Sinai, who has previously demonstrated the importance of the HLA-E/NKG2A axis as a dominant inhibitory checkpoint pathway in solid tumors. The study aims to map how CAPTN-3 antibodies alter T and NK cell activation within the TME.
Purple Biotech (NASDAQ/TASE: PPBT) has completed its previously announced registered direct offering of 472,668 American Depositary Shares (ADSs) at $6.00 per ADS, with each ADS representing 200 ordinary shares. The offering generated gross proceeds of approximately $2.8 million, before deducting placement agent fees and other expenses.
H.C. Wainwright & Co. served as the exclusive placement agent for the offering. The company plans to use the net proceeds to fund the development of its oncology therapeutic candidates and for general working capital and corporate purposes. The offering was made pursuant to a shelf registration statement previously filed with and declared effective by the SEC.
FAQ
What is the current stock price of Purple Biotech (PPBT)?
What is the market cap of Purple Biotech (PPBT)?
